Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
Status:
Terminated
Trial end date:
2009-03-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2
dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.